Users Online: 325 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Login 


RSACP wishes to inform that it shall be discontinuing the dispatch of print copy of JOACP to it's Life members. The print copy of JOACP will be posted only to those life members who send us a written confirmation for continuation of print copy.
Kindly email your affirmation for print copies to [email protected] preferably by 30th June 2019.

 

 
Table of Contents
LETTER TO EDITOR
Year : 2021  |  Volume : 37  |  Issue : 1  |  Page : 141

FDA approved ready to use phenylephrine


1 Department of Anesthesiology and Critical Care, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
2 Department of Trauma and Emergency (Anaesthesia), All India Institute of Medical Sciences, Jodhpur, Rajasthan, India

Date of Submission13-Nov-2019
Date of Acceptance19-Oct-2020
Date of Web Publication10-Apr-2021

Correspondence Address:
Dr. Ankur Sharma
Department of Trauma and Emergency (Anaesthesiology), All India Institute of Medical Sciences, Basni, Jodhpur - 342 005, Rajasthan
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/joacp.JOACP_379_19

Rights and Permissions

How to cite this article:
Bhatia PK, Sharma A. FDA approved ready to use phenylephrine. J Anaesthesiol Clin Pharmacol 2021;37:141

How to cite this URL:
Bhatia PK, Sharma A. FDA approved ready to use phenylephrine. J Anaesthesiol Clin Pharmacol [serial online] 2021 [cited 2021 May 7];37:141. Available from: https://www.joacp.org/text.asp?2021/37/1/141/313442

Dear Editor,

With reference to our previous published article,[1] we had recommended that phenylephrine should be available with prefilled syringes in lower strengths (50, 100 mcg/mL, etc.). It would have many benefits, such as being user-friendly, cost-effective, being able to draw up desired drug dilution, thus saving time in an emergent situation and reducing drug wastage compared to using a 10 mg/mL ampoule presently available.

Recently, on October 22, 2019, United States Food and Drug Administration (FDA) has approved the first prepared formulation of phenylephrine hydrocloride injection (Biorphen, Eton Pharmaceuticals) for treatment of hypotension resulting primarily from anesthesia-associated vasodilation.[2] It is available in 0.1 mg/ml strength. Similar to our recommendation, which can be given without dilution, reducing the risk of drug error in stressful medical settings. It also lowers the risk of breach of sterility and reduces waste. It can be stored up to 3 years in the operating room, emergency room, intensive care unit and in crash carts in the hospital.

It can be said that we thought ahead of times.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
  References Top

1.
Bhatia P, Kumar R, Sharma A, Chabra S, Mohammed S. A recommendation for cost-effective preparation of phenylephrine. J Anaesthesiol Clin Pharmacol 2018;34:424-5.  Back to cited text no. 1
[PUBMED]  [Full text]  
2.
Available from: www.medscape.com/viewarticle/920389. [Last accessed on 2019 Nov 13].  Back to cited text no. 2
    




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
   References

 Article Access Statistics
    Viewed134    
    Printed0    
    Emailed0    
    PDF Downloaded30    
    Comments [Add]    

Recommend this journal